Design and use of human hematopoietic prostaglandin D2 synthase inhibitors in allergic asthma and bone diseases

人造血前列腺素D2合酶抑制剂的设计及其在过敏性哮喘和骨疾病中的应用

• 批准号: nhmrc : 455949
• 负责人: Dr Jack Flanagan
• 金额: $ 34.54万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/design-use-human-bone-diseases/95211
• 关键词: Design; use; human; hematopoietic; prostaglandin

Many currently used non-steroidal anti-inflammatory drugs are burdened by side effects such as gastrointestinal bleeding or increased risk of heart attack. This is because they ablate the production of a class of molecules called prostaglandins. We believe it is possible to fine tune the action of these drugs and reduce the side effect risk. There is evidence to suggest that only some prostaglandins are involved in inflammation, so the risk of side effect can be reduced by blocking the production of only a small set. One prostaglandin, prostaglandin D2, is known to cause many characteristics of allergic asthma and may also contribute to osteoarthritis, although the evidence for this is contradictory. We will determine any therapeutic benefit to blocking the production of prostaglandin D2 in these diseases by developing compounds that only inhibit the enzyme responsible for its production.

许多目前使用的非甾体抗炎药都有副作用，如胃肠道出血或增加心脏病发作的风险。这是因为它们抑制了一类叫做前列腺素的分子的产生。我们相信有可能微调这些药物的作用，减少副作用的风险。有证据表明，只有一些前列腺素与炎症有关，因此，通过阻断一小部分前列腺素的产生，可以降低副作用的风险。一种前列腺素，前列腺素D2，已知会引起过敏性哮喘的许多特征，也可能导致骨关节炎，尽管这方面的证据是相互矛盾的。我们将通过开发仅抑制产生前列腺素D2的酶的化合物来确定阻断这些疾病中前列腺素D2产生的任何治疗益处。